Intracavitary cisplatin following pericardiocentesis may provide lasting control of malignant pericardial effusion in patients with lung cancer.
Hypothesis-generating for intracavitary cisplatin after pericardiocentesis in lung cancer; controlled trials needed before practice change.
A case of lung cancer presenting with cardiac tamponade is reported. Lasting control of the malignant effusion was achieved by means of intracavitary cisplatin following pericardiocentesis. The patient presented an objective response to subsequent systemic chemotherapy and died 10 months after the diagnosis because of disseminated cancer, without clinical or instrumental findings of pericardial effusion.
No takes yet. Share an insight, caveat, or question.
Bindi et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: